Shaanxi Meibang Pharmaceutical Group Co., Ltd. (605033.SS)
CNY 12.67
(-0.63%)
CNY 12.67
(-0.63%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | 50.36 Million CNY | -64.09% |
| 2022 | 140.27 Million CNY | 14.51% |
| 2021 | 122.5 Million CNY | 39.85% |
| 2020 | 87.59 Million CNY | 1.8% |
| 2019 | 86.04 Million CNY | 28.7% |
| 2018 | 66.86 Million CNY | -4.32% |
| 2017 | 69.87 Million CNY | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | -6.77 Million CNY | -113.68% |
| 2024 Q3 | -1.4 Million CNY | 79.2% |
| 2024 Q1 | 49.55 Million CNY | 246.25% |
| 2023 Q2 | 7.74 Million CNY | -90.22% |
| 2023 FY | 50.36 Million CNY | -64.09% |
| 2023 Q4 | -33.88 Million CNY | -1122.29% |
| 2023 Q3 | -2.77 Million CNY | -135.77% |
| 2023 Q1 | 79.27 Million CNY | 220.47% |
| 2022 Q3 | -18.67 Million CNY | -197.31% |
| 2022 Q2 | 19.19 Million CNY | -82.06% |
| 2022 Q1 | 106.98 Million CNY | 126.69% |
| 2022 FY | 140.27 Million CNY | 14.51% |
| 2022 Q4 | 24.73 Million CNY | 232.45% |
| 2021 FY | 122.5 Million CNY | 39.85% |
| 2021 Q4 | 47.19 Million CNY | 1085.69% |
| 2021 Q3 | -4.78 Million CNY | -118.87% |
| 2021 Q2 | 25.37 Million CNY | -53.63% |
| 2021 Q1 | 54.72 Million CNY | 114.52% |
| 2020 FY | 87.59 Million CNY | 1.8% |
| 2020 Q4 | 25.51 Million CNY | 319.67% |
| 2020 Q3 | -11.61 Million CNY | -149.55% |
| 2020 Q2 | 23.43 Million CNY | -53.36% |
| 2020 Q1 | 50.25 Million CNY | 0.0% |
| 2019 FY | 86.04 Million CNY | 28.7% |
| 2018 FY | 66.86 Million CNY | -4.32% |
| 2017 FY | 69.87 Million CNY | 0.0% |